These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1180 related articles for article (PubMed ID: 21090814)

  • 1. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
    Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.
    Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.
    Szczepankiewicz BG; Kosogof C; Nelson LT; Liu G; Liu B; Zhao H; Serby MD; Xin Z; Liu M; Gum RJ; Haasch DL; Wang S; Clampit JE; Johnson EF; Lubben TH; Stashko MA; Olejniczak ET; Sun C; Dorwin SA; Haskins K; Abad-Zapatero C; Fry EH; Hutchins CW; Sham HL; Rondinone CM; Trevillyan JM
    J Med Chem; 2006 Jun; 49(12):3563-80. PubMed ID: 16759099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
    Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of bi-thiazole-2,2'-diamines as kinase inhibitory scaffolds.
    Ngoei KR; Ng DC; Gooley PR; Fairlie DP; Stoermer MJ; Bogoyevitch MA
    Biochim Biophys Acta; 2013 Jun; 1834(6):1077-88. PubMed ID: 23410953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase.
    Laufer S; Lehmann F
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1461-4. PubMed ID: 19195885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
    Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
    J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
    Patel SB; Cameron PM; O'Keefe SJ; Frantz-Wattley B; Thompson J; O'Neill EA; Tennis T; Liu L; Becker JW; Scapin G
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):777-85. PubMed ID: 19622861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
    Badrinarayan P; Sastry GN
    J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
    Frembgen-Kesner T; Elcock AH
    J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
    Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
    J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
    Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
    J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.